Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$22.20M-15.97%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John D. Duke
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 328
- Beta
- 1.47
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.66
Financials
Revenue
$22.20M-16.0%Net Income
$-2.62MEBITDA
$-912.0K-680.9%Free Cash Flow
$-1.18M-197.8%EPS (diluted)
$-0.58Shares Outstanding (diluted)
4.56M+32.7%Operating Expenses
$12.43MCash & Debt
$4.86MReturn of Capital
$0.00Revenue by Segment (annual)
$86.55MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $86.55M | $-56.70M | $-12.80 |
| 2024 | $94.14M | $-12.40M | $-2.80 |
| 2023 | $112.25M | $-3.42M | $-0.81 |
| 2022 | $113.33M | $-9.52M | $-2.30 |
| 2021 | $118.90M | $-288.0K | $-0.07 |
| 2020 | $102.10M | $-7.81M | $-2.00 |
| 2019 | $116.18M | $-4.69M | $-1.20 |
| 2018 | $120.77M | $-3.46M | $-0.97 |
| 2017 | $101.88M | $-865.0K | $-0.26 |
| 2016 | $104.52M | $-4.31M | $-1.30 |
| 2015 | $108.66M | $-19.04M | $-5.70 |
| 2014 | $108.66M | $2.35M | $0.70 |
| 2013 | $105.17M | $-1.83M | $-0.60 |
| 2012 | $111.17M | $2.37M | $0.90 |
Valuation
HBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·12d ago·Positive
Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will participate in Canaccord Genuity's MedTech, Diagnostics, and Digital Health and Services Forum on November 11th, 2026.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Harvard Bioscience Announces Creation of Scientific Advisory Board HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company's ongoing research, development, and new product roadmaps.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.00 per share
Typical surprise +46.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.06 vs $-0.33beat
- Tue, Aug 11$-0.14 vs $-0.21beat
- Tue, May 12$-0.33 vs $-0.62beat
- Thu, Mar 12$-0.64 vs $0.04miss
- Thu, Nov 6$-0.28 vs $0.05miss
- Mon, Aug 11$-0.10 vs $-0.25beat
Estimates and results for HBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HBIO officers and directors.
- Bought
- $1.1m
- Sold
- —
23 trades
0 trades
- Denelsky Stephen Jbought
- Snider Williambought
- Frost Mark Tbought
- Snider Williambought
- Duke John Dbought
- Green James Wbought
- Green James Wbought
- Green James Wbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HBIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
